12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Seroquel XR quetiapine regulatory update

FDA updated the label of atypical antipsychotic drug Seroquel XR quetiapine from AstraZeneca to warn about the risk of QT prolongation when given in combination with other drugs that are known to prolong QT. The agency also warned that Seroquel XR...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >